ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Kudchadkar Discusses Melanoma Testing

Ragini Kudchadkar, MD
Published: Thursday, Oct 17, 2013

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses testing for melanoma.

If a patient with melanoma is not on a clinical trial, Kudchadkar says, they need to be tested to see if they have a chance to benefit from a targeted therapy. Though BRAF mutational status is typically looked at in patients with stage IV disease, most physicians believe that a high-risk patient with stage III disease should also be tested. This population of patients has a high risk of recurrence, Kudchadkar says, sometimes as high as 70%. Kudchadkar says she does not recommend testing patients with early stage disease, as they can be cured with surgery alone.

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses testing for melanoma.

If a patient with melanoma is not on a clinical trial, Kudchadkar says, they need to be tested to see if they have a chance to benefit from a targeted therapy. Though BRAF mutational status is typically looked at in patients with stage IV disease, most physicians believe that a high-risk patient with stage III disease should also be tested. This population of patients has a high risk of recurrence, Kudchadkar says, sometimes as high as 70%. Kudchadkar says she does not recommend testing patients with early stage disease, as they can be cured with surgery alone.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x